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Abstract
The aim of the study: to study and demonstrate the potential and technical aspects of the surgical treatment of locally ad-
vanced thymus tumours with the tumour infiltrate affecting superior vena cava and its branches.
Methods. 56 patients with locally advanced thymomas complicated by SVCS were study. The control group included 
30 patients with SVCS were treated with conventional techniques, while the experimental group included 26 patients who underwent 
a novel bypass surgery developed by us. 
Results. Based on our observations, patients tolerated these surgeries much better. The venous bypass was mandatorily 
complemented with cytoreduction. Auriculo-jugular (left and right) and auriculo-subclavian (left and right) bypasses were used 
in our observations
Complications in the post-operative period were reported from the experimental group and included auriculo-subclavian 
bypass thrombosis, post-operative complications were reported in the control group including haemorrhage from the sternotomy 
wound in 1 (3.3 %) case, superior vena cava thrombosis in 2 (6.6 %) cases, pneumonia in 2 (6.6 %) cases and thromboembolism of 
small pulmonary arteries in 2 (6.6 %) cases. 
Post-operative lethality in the study groups was reported in the control and in the experimental group. Total lethality rate was 
8.9 % (5 patients). The relative risk of complications and lethal outcome was calculated for patients from both groups. It was found that 
the risk of complications was twice as high in the control group as in the experimental group (standard error of relative risk equals 0.64), 
whereas the risk of lethal outcome increased by a factor of 3.5 in the control group (standard error of relative risk equals 1.09).
Conclusion. It has been established that the superior vena cava syndrome in patients with locally advanced thymoma is an 
emergency condition whose surgical correction must be personalised depending on the anatomic and topographic classification of 
SVC lesion types. It is known that an obligatory pre-condition of the perioperative period in this category of patients is an adequate 
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vascular approach to the superior vena cava system. The first mandatory step of the radical surgery in patients with locally advanced 
thymomas with SVC invasion should be the auriculo-jugular and auriculo-subclavian bypasses, which can reduce the relative risk of 
post-operative complications by a factor of the risk of lethal by a factor of 3.5.
Keywords: superior vena cava syndrome, thymoma, surgical treatment, postoperation complication, radical surgery, bypass.
DOI: 10.21303/2504-5679.2021.001852
1. Introduction
The superior vena cava syndrome (SVCS) was first described in 1757 [1, 2]. Reduced blood 
flow in the superior vena cava (SVC) system decreases the amount of venous blood in the right 
auricle, causing a number of clinical characteristics and symptoms, such as dilated neck veins, 
oedematous upper limbs, cyanosis, headache, dyspnoea, cough, and dysphagia [3, 4]. Impaired 
blood flow may be caused by external compression, direct tumour invasion, thrombosis, or inef-
fective venous return as a consequence of diseases affecting the right auricle or the vessel lumen 
itself. Over time, the main role in the aetiology of this syndrome shifted from tuberculosis and 
syphilitic aneurisms, prevalent in the beginning of the 20th century, to locally advanced mediasti-
num tumours, such as thymomas [5]. In the USA, 15,000 new SVCS cases are reported annually, 
up to 85 % of which are developed due to a primary or secondary tumour lesion. Around 73–85 % 
of all CVCS cases of tumour genesis are due to locally advanced thymomas [6, 7].
The first reliable description of the clinical profile of SVCS was provided by W. Hun-
ter (1757) [8, 9]. Further numerous works of foreign and Ukrainian authors considerably expanded 
the understanding of the origin of this syndrome; however, surgical treatment methods were not used 
until the middle or end of the previous century. The first mentions of successful azygo-atrial anasto-
mosis for SVCS date back to 1951 [10, 11]. In the same year, Sampsen combined the azygos vein with 
the right atrium using venous autotransplant. A successful application of a synthetic transplant for 
the plastic replacement of superior vena cava was first reported by Blondean et al. in 1959 [12, 13].
SVCS is also an emergency condition related to impaired blood flow in the SVC system and 
being one of the variants of compression mediastinum syndrome [14, 15]. The disease is clinically 
manifested as SVCS, uni- or bilateral Paget-Schroetter syndrome. Progressive venous oedema of the 
upper half of the body and upper limbs significantly deteriorates brain haemodynamics, which can 
lead to brain oedema and herniation [16, 17]. Taking into account the fact that, with the development 
of circulatory hypoxia, the blood flow to the right heart compartments, the circulating blood vo-
lume (CBV) and the cardiac output are reduced, this type of tumour can be considered a life-threat-
ening condition [18, 19]. Previously, the tactics in this clinical situation included chemo- and radiation 
therapy. Experience shows that these conservative measures require much time, while thymomas may 
be resistant to chemo- and radiation therapy. We have recently adopted active personalised surgical 
tactics, which largely depends on the interaction between the tumour, SVC and its branches [20].
The aim of the study is to demonstrate the potential and technical aspects of the surgical 
treatment of locally advanced thymus tumours with the tumour infiltrate affecting superior vena 
cava and its branches.
2. Materials and research methods
The study is a retrospective analysis of observation data involving 56 patients with locally 
advanced thymomas complicated by SVCS who were treated at the Department of Thoracoab-
dominal Surgery of the State Institution «Zaycev V. T. Institute of General and Urgent Surgery 
of the National Academy of Medical Sciences of Ukraine» between 2014 and 2020. The control 
group included 30 patients with SVCS treated with conventional techniques, while the experimen-
tal group included 26 patients who underwent a novel bypass surgery developed by us.
The authors declare that all procedures and experiments of this study respect the ethical 
standards in the Helsinki Declaration of 1975, as revised in 2008 (5), as well as the national law. In-
formed consent to participate in the study was discussed and signed by all study participants. Meet-
ing of the Bioethics Commission (protocol No. 2 11.03.2021) of the State Institution «Zaycev V. T. 
Institute of General and Urgent Surgery of the National Academy of Medical Sciences of Ukraine».
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At the preoperative stage, all patients underwent standard diagnostic tests to assess the 
advancement of the tumour process in the mediastinum and functional reserves: multislice com-
puted tomography (MSCT) of thoracic and abdominal organs, comprehensive ultrasound test (in-
cluding mediastinum ultrasound), electrocardiography, echocardiography, spirometry. Fiber-optic 
bronchoscopy was performed in case of lung lesion. The most reliable method of diagnosing SVC 
invasion at the pre-operative stage and assessing tumour advancement is considered to be MSCT 
with intravenous contrast enhancement with iso-osmolar contrast, which does not cause a sharp 
blood pressure drop that is likely to cause a vascular collapse at the backdrop of reduced heart flow. 
SVC invasion is most precisely visualized in the early venous phase. Echocardiography is required 
to identify a tumour thrombus in the mediastinum. Besides, patients obligatorily underwent dop-
pler ultrasound test of upper limb and neck vessels. 
There was not found a significant difference in the number of patients, average age, gender 
composition, or body mass index (BMI) found between ОА groups (p > 0.05).
The femoral vein was catheterized to ensure continuous venous access, and the subclavian 
and the jugular veins were catheterized to monitor the central venous pressure. 
Taking into account the anatomical and topographic features of superior vena cava and 
inflowing veins, we have developed a classification of SVC lesion types (working classification of 
SI «Zaycev V. T. Institute of General and Urgent Surgery of the NAMS of Ukraine») (Fig. 1).
Fig. 1. Types of lesions of superior vena cava and its branches
According to the classification, 4 types of SVC lesions were singled out. Type I stands for le-
sions in the left brachiocephalic vein, subclavian and jugular veins (uni- or bilateral); Type II stands 
for lesions in the upper SVC segment; Type III stands for lesions in the middle SVC segment; 
Type IV stands for lesions in the lower SVC segment. Table 1 presents the distribution of patients 
in the experimental and control groups depending on the SVC lesion type. The difference bet-
ween the groups by lesion types is not statistically significant (the chi-squared value equals 0.48 at 
p-value = 0.92). There was not found a significant difference in the number of patients, average age, 
gender composition, or body mass index (BMI) found between ОА groups (p > 0.05).
Table 1
Structure of study groups according to the SVC lesion type
SVC lesion type
Experimental group n = 26 Control group n = 30
n % n %
Type 1 10 (38.5 %) 9 (30 %)
Type II 8 (30.8) 10 (33.3 %)
Type III 6 (23 %) 8 (26.7 %)
Type IV 2 (7.7 %) 3 (10 %)













The studied group are equivalent and comparable in terms of basic prognosis criteria, sex, 
age, stage of tumor and localization, as well as by the degree of severity of clinical signs.
Patients in the study groups also had concomitant diseases that significantly influ-
enced the course of the main disease, patients’ preparation for the surgery and characteristics 
of the peri- and postoperative period. All concomitant diseases were identified at the pre-hos-
pital stage thanks to thorough examination. Cardiovascular diseases were the most common 
in 22 (39.3 %), (p < 0.05) patients (hypertension, ischemic heart disease, various arrhythmias) 
followed by respiratory diseases in 9 (16.1 %), (p < 0.05) patients (pulmonary emphysema, 
chro nic obstructive pulmonary disease, bronchial asthma); myasthenia in 14 (25 %), (p < 0.05) 
patients, diabetes mellitus in 7 (12.5 %), (p < 0.05) patients, and thyroid gland diseases 
in 5 (8.9 %), (p < 0,05) patients (multinodular euthyroid goiter, autoimmune thyroiditis). The 
structure of concomitant pathologies is provided in Table 2. It should be noted that one pa-
tient can have several concomitant pathologies, but the table includes only the most pronounced 
ones. The difference between groups by concomitant pathology types is not statistically signi-
ficant (the chisquared value equals 2.14 at p-value = 0.71). The differences between the main and 
control groups are statistically significant (p < 0.05) (Table 1).
Table 2
Structure of concomitant pathologies in study groups
Concomitant diseases Experimental group n = 26 Control group n = 30
Cardiovascular diseases 12 (46.2 ± 0.5 %) 10 (33.4 ± 0.3 %)
Respiratory diseases 4 (15.3 ± 0.1 %) 4 (13.3 ± 0.2 %)
Myasthenia 6 (23.1 ± 0.3 %) 8 (26.7 ± 0.1 %)
Diabetes mellitus 3 (11.5 ± 0.3 %) 4 (13.3 ± 0.01 %)
Thyroid gland diseases 1 (3.9 ± 0.01 %) 4 (13.3 ± 0.01 %)
The differences between the main and control groups are statistically signifi- 
cant (p < 0.05) (Table 2).
In order to assess the operative risk of complications in patients from the study groups, the 
ASA physical status classification system was used. We used the scale from the 2014 revision. 
The distribution of patients depending on the risk score is presented in Table 3. The difference 
between groups by the perioperative risk score is not statistically significant (the chi-squared value 
equals 0.04 at p-value = 0.98). 
Table 3
Distribution of patients in the study group by the perioperative risk score (ASA)
Perioperative risk score
Patient group
Experimental group (n = 26) Control group (n = 30) Total (n = 56)
ASA II 17 (65.4 ± 0.2 %) 20 (66.7 ± 0.1 %) 37 (66.1 ± 0.3 %)
ASA III 6 (23.1 ± 0.1 %) 7 (23.3 ± 0.2 %) 13 (23.2 ± 0.2 %)
ASA IV 3 (11.5 ± 0.3 %) 3 (10.0 ± 0.3 %) 6 (10.7 ± 0.01 %)
Taking into account data from Table 3, it can be observed that most of the patients under 
study had ASA grade II and III of the perioperative risk. There were no significant differences 
between study groups in terms of lesion types, concomitant pathologies, and perioperative risk 
score (p < 0.05). The differences between the main and control groups are statistically signifi-
cant (p < 0.05) (Table 3).
Patients from study groups underwent surgeries after thorough examination and assessment 
of the operative risk. The structure of surgical interventions is described in Table 4.
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Structure of surgical interventions in study groups
Tactics Experimental group (n = 26) Control group
Explorative interventions with biopsy – 6 (20 ± 0,2 %)
Decompression cytoreductive interventions – 4 (3.3 ± 0,1 %)
Bypass surgeries 12 (46.2 ± 0.5 %) –
Extended thymectomy with brachiocephalic vein resection 9 (34.6 ± 0,1 %) 13 (43.3 ± 0.3 %)
Extended thymectomy with superior vena cava resection 5 (19.2 ± 0.3 %) 7 (23.4 ± 0.2 %)
Ethics review. All patients signed a voluntary informed consent for the examination and treat-
ment, as well as publication of anonymized personal medical information for academic purposes.
Statistical analysis. Findings concerning the effectiveness of different surgical interventions 
were analysed using non-parametric statistical techniques (analysis of two-dimensional frequency 
distributions based on the chi-squared criterion and relative risk) in R and RStudio free-access 
software for statistical calculations and MS Excel spreadsheet processor. The differences between 
the main and control groups are statistically significant (p < 0.05) (Table 4).
3. Results
Ensuring adequate vascular approach to inject medicines, carry out infusion therapy and 
perform anaesthesia is crucial in the perioperative period of patients with locally advanced thymo-
mas with SVCS. Traditional infusion in the SVC system veins significantly increases venous hy-
pertension and oedema of the upper half of the body. To avoid this, femoral veins were catheterized 
and the medicines were administered intra-arterially (mostly in the radial artery). In patients from 
the experimental group, where the tumour could not be resected for technical reasons, venous by-
pass was performed to correct SVCS. Based on our observations, patients tolerated these surgeries 
much better. The venous bypass was mandatorily complemented with cytoreduction. Auriculo- 
jugular (left and right) and auriculo-subclavian (left and right) bypasses were used in our observa-
tions (Fig. 2). Since invasive thymomas are most commonly located on the left side [2], left-side 
bypasses were used more often in SVCS correction.
Fig. 2. Auriculo-jugular (1) and auriculo-subclavian (2) bypasses
In 5 (19.2 %) cases, the auriculo-jugular bypass was used as an auxiliary stage in radical 
resection of locally advanced thymoma tumours. In our opinion, resecting a tumour with SVC in-
vasion without a prior bypass is a mistake that may cause a lethal outcome. SVC transection or its 
acute thrombosis during the tumour resection causes a rapid increase in the central venous pressure 
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with all the ensuing consequences. In certain cases, the near-tumoral thrombus or tumoral tissue 
may get detached and migrate to the right heart compartments, leading to the development of the 
pulmonary embolism. Therefore, type I, II and III tumour invasions in the SVC were considered 
clinical situations, for which the auriculo-jugular bypass was mandatory as the first stage of a ra-
dical surgery. An important pre-condition of a SVC surgery is the observation of measures aimed 
to prevent embolic complications. To introduce a prosthesis to the blood flow, first the forceps from 
the proximal bypass segment are removed, then, after the prosthesis is filled with blood and free 
from air, the distal forceps located closer to the auricle are removed. While exploring the technique 
of resecting locally advanced thymomas with SVC invasion, we used the full vertical sternotomy 
approach extended to the neck along the sternocleidomastoid muscle.
 Later, such traumatic approach could be avoided: the proximal anastomosis was formed 
from a mini-approach on the neck, and the distal one from the sternotomy approach. In the case of 
large tumours, their resection was only possible after a pericardium incision and specification of 
the tumour invasion degree from the pericardial cavity. Depending on the degree of pericardium 
lesion, limited pericardiectomy was performed in the invasion area with the resection of 1/3, 2/3 
and 3/4 of affected pericardium; in 2 (7.7 %) patients, full pericardiectomy was performed. In all 
cases of extended thymectomies, we aimed to preserve diaphragmatic nerves. In case of tumour 
invasion in the azygos vein, it was preliminarily secured. In Type IV tumour invasion in SVC, it is 
crucial to preserve the auricular SVC segment that includes the synoauricular node. If this segment 
cannot be preserved for technical reasons and must be resected, epicardial electrocardiostimulation 
is indicated, which can be substituted with endocardial stimulation if necessary.
Taking into account that all patients belonged to stage III-IV of the tumour process extent 
according to Masaoka-Koga’s classification, during the post-operative period the patients under-
went external-beam radiation therapy according to the split-extended scheme with fraction radia-
tion with single boost dose (SBD) = 2 Gy once a week up to total boost dose (TBD) = 40–45 Gy (in 
radical interventions) and SBD = 2 Gy 5 times a week up to TBD 60–70 Gy. Chemotherapy was 
used in combination with radiation therapy in 11 (19.7 %) patients after cytoreductive and explo-
rative interventions.
Complications in the post-operative period were reported in 3 (11.5 %) patients from the 
experimental group and included auriculo-subclavian bypass thrombosis in 1 (3.8 %) case, pneu-
monia in 1 (3.8 %) case and thromboembolism of small pulmonary arteries in 1 (3.8 %) case. 
7 (23.4 %) post-operative complications were reported in the control group including haemorrhage 
from the sternotomy wound in 1 (3.3 %) case, superior vena cava thrombosis in 2 (6.6 %) cases, 
pneumonia in 2 (6.6 %) cases and thromboembolism of small pulmonary arteries in 2 (6.6 %) cases.
Post-operative lethality in the study groups was reported for 4 (13.3 %) patients in the con-
trol group and 1 (3.8 %) patient in the experimental group. Total lethality rate was 8.9 % (5 pa-
tients). The causes of post-operative lethality included myasthenic crisis in 1 (1.8 %) patient, pneu-
monia in 1 (1.8 %) patient, myocardial infarction in 1 (1.8 %) patient, and pulmonary embolism 
in 2 (3.6 % patients).
The relative risk of complications and lethal outcome was calculated for patients from both 
groups. It was found that the risk of complications was twice as high in the control group as in the 
experimental group (standard error of relative risk equals 0.64), whereas the risk of lethal outcome 
increased by a factor of 3.5 in the control group (standard error of relative risk equals 1.09).
4. Discussion
In our research, which is a retrospective analysis of observation of the results of surgi-
cal treatment for 56 patients with locally advanced thymomas complicated by SVCS. The control 
group included 30 patients with SVCS treated with conventional techniques, while the experimen-
tal group included 26 patients who underwent a new bypass surgery developed by us.
In patients with locally advanced thymomas, constantly increased pressure in the SVC sys-
tem for several months leads to progressive dilatation and development of a network of collateral 
venous blood flow. Owing to this mechanism, the SVCS remains at the compensation or subcom-
pensation stage for a rather long time [15].
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It should be noted that in the structure of complications in the post-operative period in our 
study, the leading place is occupied by auriculo-subclavian bypass thrombosis in 3.8 % of patients. 
So, in our study, pneumonia was in 3.8 % of patients. Thromboembolism of small pulmonary ar-
teries in 3.8 % of patients whereas in 23.4 % of patients post-operative complications were reported 
in the control group including haemorrhage from the sternotomy wound in 3.3 % of patients. Also, 
superior vena cava thrombosis in 6.6 % of patients while pneumonia in 6.6 % of patients. However, 
thromboembolism of small pulmonary arteries in 6.6 % of patients [3, 10]. 
Study limitations. This study combines the results of a retrospective analysis of observa-
tion of the results of surgical treatment patients with locally advanced thymomas complicated by 
SVCS. Since the use of the venous bypass to improve results in the postoperative period and realize 
the full effect of treatment in patients. 
Prospects for the future research. Since the usage of by-pass methods of surgical treat-
ment and conservative treatment patients with locally advanced thymomas complicated by SVCS 
can notice to improving of surgical results, we plan to develop an algorithm that will reduce the 
number of postoperative complications.
5. Conclusions
The superior vena cava syndrome in 56 patients (26 (46 %) in the experimental group and 
30 (54 %) in the control group) with locally advanced thymoma is an emergency condition whose 
surgical correction must be personalised depending on the anatomic and topographic classification 
of SVC lesion types.
An obligatory pre-condition of the perioperative period in this category of patients is an 
adequate vascular approach to the superior vena cava system.
The first mandatory step of the radical surgery in patients with locally advanced thymomas 
with SVC invasion should be the auriculo-jugular ASA II 37 (66.1 %), (p < 0.05) and auriculo- 
subclavian bypasses in 13 (23.2 %), (p < 0.05) which can reduce the relative risk of post-operative 
complications by a factor of 2 and the risk of lethal by a factor of 3.5. 
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